Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Offers Free Genetic Mutation Testing for Some Melanoma Patients

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 02:08pm EDT

By Stephen Nakrosis

Novartis AG (NVS) said Thursday it is offering free genetic testing to patients with Stage III and Stage IV melanoma, to determine if the patients have a genetic mutation which could impact their treatment options.

The "Know Now Testing Program" will enable patients to determine if they carry a specific mutation, called BRAF.

"At Novartis, we know that understanding potential mutations is critical for melanoma patients and their doctors to make informed treatment decisions," said Ameet Mallik, Executive Vice President and Head, U.S., Novartis Oncology.

Test results will be available about 48 hours after a Quest Diagnostics laboratory receives a sample, Novartis said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10:14aNOVARTIS : key multiple sclerosis Product Gilenya approved in China
AQ
01:16aNOVARTIS : Sandoz announces first patient enrolled in clinical study for propose..
GL
07/19ALCON : Novartis delivers strong sales, double digit core operating income growt..
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19NOVARTIS : key multiple sclerosis product Gilenya® approved in China
PU
07/18EUROPE : ECB report eases earnings pain for European stocks
RE
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18GLOBAL MARKETS LIVE : Microsoft, Qualcomm, Netflix, Facebook…
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18Weak Earnings, Trade Tensions Weigh on Global Stocks
DJ
More news
Financials (USD)
Sales 2019 46 888 M
EBIT 2019 13 811 M
Net income 2019 10 249 M
Debt 2019 17 311 M
Yield 2019 3,21%
P/E ratio 2019 24,7x
P/E ratio 2020 21,8x
EV / Sales2019 4,89x
EV / Sales2020 4,56x
Capitalization 212 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 93,30  $
Last Close Price 92,50  $
Spread / Highest target 16,2%
Spread / Average Target 0,87%
Spread / Lowest Target -17,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS24.78%216 273
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
MERCK AND COMPANY6.52%209 550